Kevin Deane
Concepts (472)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 126 | 2026 | 1168 | 18.890 |
Why?
| | Autoantibodies | 69 | 2026 | 1497 | 7.830 |
Why?
| | Anti-Citrullinated Protein Antibodies | 31 | 2026 | 126 | 6.920 |
Why?
| | Rheumatoid Factor | 42 | 2026 | 175 | 5.520 |
Why?
| | Peptides, Cyclic | 32 | 2026 | 275 | 3.570 |
Why?
| | Antirheumatic Agents | 13 | 2026 | 303 | 3.230 |
Why?
| | Autoimmunity | 23 | 2025 | 924 | 3.080 |
Why?
| | Malaria | 3 | 2025 | 73 | 1.760 |
Why?
| | Sputum | 5 | 2025 | 308 | 1.620 |
Why?
| | Rheumatic Diseases | 4 | 2022 | 97 | 1.610 |
Why?
| | Methotrexate | 5 | 2025 | 240 | 1.490 |
Why?
| | Lung Diseases, Interstitial | 11 | 2025 | 659 | 1.320 |
Why?
| | Hydroxychloroquine | 3 | 2026 | 63 | 1.280 |
Why?
| | Humans | 164 | 2026 | 144261 | 1.210 |
Why?
| | Biomarkers | 32 | 2026 | 4254 | 1.170 |
Why?
| | Disease Progression | 21 | 2026 | 2840 | 1.150 |
Why?
| | Immunoglobulin A | 11 | 2023 | 214 | 1.110 |
Why?
| | Arthralgia | 4 | 2025 | 61 | 1.100 |
Why?
| | Autoimmune Diseases | 5 | 2024 | 463 | 1.050 |
Why?
| | HIV Infections | 5 | 2023 | 3079 | 1.040 |
Why?
| | Autoantigens | 8 | 2023 | 429 | 0.950 |
Why?
| | Inflammation | 11 | 2025 | 2877 | 0.860 |
Why?
| | Middle Aged | 77 | 2026 | 35762 | 0.860 |
Why?
| | Female | 101 | 2026 | 77976 | 0.850 |
Why?
| | Social Determinants of Health | 2 | 2025 | 299 | 0.850 |
Why?
| | Male | 88 | 2026 | 72035 | 0.850 |
Why?
| | Bronchial Diseases | 3 | 2013 | 38 | 0.830 |
Why?
| | Early Medical Intervention | 2 | 2014 | 61 | 0.830 |
Why?
| | Risk Factors | 36 | 2026 | 10699 | 0.820 |
Why?
| | Extracellular Traps | 3 | 2021 | 57 | 0.800 |
Why?
| | Genetic Predisposition to Disease | 16 | 2023 | 2359 | 0.790 |
Why?
| | Rheumatology | 7 | 2025 | 132 | 0.760 |
Why?
| | Mucous Membrane | 2 | 2024 | 127 | 0.730 |
Why?
| | Early Diagnosis | 8 | 2022 | 247 | 0.720 |
Why?
| | Lung Diseases | 4 | 2022 | 787 | 0.720 |
Why?
| | Adult | 62 | 2026 | 40262 | 0.710 |
Why?
| | Mosquito Vectors | 1 | 2022 | 28 | 0.710 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 231 | 0.700 |
Why?
| | Insecticides | 1 | 2022 | 42 | 0.700 |
Why?
| | Lupus Erythematosus, Systemic | 4 | 2022 | 239 | 0.700 |
Why?
| | Case-Control Studies | 19 | 2025 | 3592 | 0.690 |
Why?
| | Joints | 4 | 2015 | 107 | 0.670 |
Why?
| | Precision Medicine | 3 | 2020 | 456 | 0.670 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 21 | 0.660 |
Why?
| | Epitopes | 8 | 2023 | 485 | 0.640 |
Why?
| | Aged | 45 | 2026 | 25850 | 0.620 |
Why?
| | Qualitative Research | 6 | 2025 | 1659 | 0.600 |
Why?
| | Citrullination | 2 | 2020 | 13 | 0.590 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 850 | 0.580 |
Why?
| | Histones | 4 | 2023 | 668 | 0.580 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 249 | 0.580 |
Why?
| | Lung | 7 | 2020 | 4108 | 0.570 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 244 | 0.530 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 97 | 0.520 |
Why?
| | Immunoglobulin G | 11 | 2023 | 893 | 0.520 |
Why?
| | Transgender Persons | 1 | 2020 | 190 | 0.520 |
Why?
| | Pedigree | 2 | 2020 | 513 | 0.510 |
Why?
| | Citrulline | 2 | 2016 | 46 | 0.500 |
Why?
| | Focus Groups | 4 | 2025 | 569 | 0.500 |
Why?
| | Synovitis | 2 | 2023 | 33 | 0.490 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2015 | 51 | 0.490 |
Why?
| | Human Migration | 1 | 2016 | 25 | 0.480 |
Why?
| | Transients and Migrants | 1 | 2016 | 27 | 0.480 |
Why?
| | B-Lymphocytes | 4 | 2025 | 876 | 0.480 |
Why?
| | Rituximab | 3 | 2025 | 209 | 0.470 |
Why?
| | Arthritis | 2 | 2016 | 96 | 0.460 |
Why?
| | Synovial Membrane | 4 | 2025 | 124 | 0.460 |
Why?
| | Prospective Studies | 22 | 2025 | 7970 | 0.450 |
Why?
| | Immunoglobulin M | 7 | 2023 | 284 | 0.450 |
Why?
| | Th17 Cells | 3 | 2025 | 100 | 0.440 |
Why?
| | Abatacept | 2 | 2025 | 56 | 0.420 |
Why?
| | Cytokines | 10 | 2023 | 2061 | 0.420 |
Why?
| | Sexual Behavior | 2 | 2016 | 484 | 0.420 |
Why?
| | Antipsychotic Agents | 1 | 2016 | 207 | 0.410 |
Why?
| | Pneumonia | 1 | 2020 | 630 | 0.410 |
Why?
| | Family | 7 | 2021 | 679 | 0.400 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 878 | 0.400 |
Why?
| | Psychotic Disorders | 1 | 2016 | 182 | 0.400 |
Why?
| | Risk-Taking | 1 | 2016 | 323 | 0.390 |
Why?
| | Chemokines | 2 | 2012 | 218 | 0.390 |
Why?
| | Endothelium, Vascular | 4 | 2013 | 963 | 0.380 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2013 | 47 | 0.380 |
Why?
| | Risk Assessment | 9 | 2025 | 3637 | 0.370 |
Why?
| | Tanzania | 3 | 2021 | 62 | 0.370 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 225 | 0.370 |
Why?
| | Hazardous Substances | 1 | 2012 | 15 | 0.370 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 129 | 0.360 |
Why?
| | Mass Screening | 4 | 2025 | 1332 | 0.350 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.340 |
Why?
| | Smoking | 9 | 2024 | 1468 | 0.340 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 142 | 0.330 |
Why?
| | Gene-Environment Interaction | 1 | 2012 | 180 | 0.330 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 83 | 0.320 |
Why?
| | Malondialdehyde | 2 | 2020 | 30 | 0.320 |
Why?
| | Acetaldehyde | 2 | 2020 | 17 | 0.320 |
Why?
| | Mucin-5B | 3 | 2025 | 234 | 0.310 |
Why?
| | Protein Processing, Post-Translational | 1 | 2013 | 477 | 0.310 |
Why?
| | Health Fairs | 1 | 2009 | 10 | 0.310 |
Why?
| | Antibodies, Antinuclear | 5 | 2023 | 62 | 0.310 |
Why?
| | Research Design | 3 | 2024 | 1129 | 0.310 |
Why?
| | Social Stigma | 2 | 2023 | 158 | 0.310 |
Why?
| | Emigration and Immigration | 1 | 2010 | 66 | 0.310 |
Why?
| | Incidence | 10 | 2026 | 2870 | 0.310 |
Why?
| | Postmenopause | 7 | 2023 | 391 | 0.310 |
Why?
| | Glucocorticoids | 3 | 2021 | 533 | 0.290 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2025 | 1217 | 0.290 |
Why?
| | Antibodies, Bacterial | 3 | 2023 | 148 | 0.280 |
Why?
| | Uganda | 2 | 2025 | 91 | 0.280 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1050 | 0.270 |
Why?
| | Cross-Sectional Studies | 10 | 2025 | 5813 | 0.260 |
Why?
| | Interviews as Topic | 3 | 2025 | 898 | 0.260 |
Why?
| | Health Behavior | 3 | 2018 | 782 | 0.260 |
Why?
| | B-Cell Activating Factor | 2 | 2024 | 21 | 0.260 |
Why?
| | Animals | 12 | 2025 | 38030 | 0.250 |
Why?
| | Chlamydia trachomatis | 2 | 2025 | 49 | 0.240 |
Why?
| | Antibody Formation | 4 | 2023 | 294 | 0.240 |
Why?
| | Immunophenotyping | 2 | 2025 | 322 | 0.240 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 24 | 0.230 |
Why?
| | Qa-SNARE Proteins | 1 | 2025 | 19 | 0.230 |
Why?
| | Developing Countries | 2 | 2025 | 314 | 0.230 |
Why?
| | Chlamydia Infections | 2 | 2025 | 81 | 0.230 |
Why?
| | Vasculitis | 1 | 2005 | 68 | 0.220 |
Why?
| | HLA-B27 Antigen | 1 | 2024 | 16 | 0.220 |
Why?
| | Arthritis, Psoriatic | 1 | 2024 | 15 | 0.220 |
Why?
| | Complement Factor H | 1 | 2025 | 80 | 0.210 |
Why?
| | Longitudinal Studies | 5 | 2025 | 2926 | 0.210 |
Why?
| | Complement Activation | 2 | 2025 | 411 | 0.210 |
Why?
| | Spondylarthritis | 1 | 2024 | 50 | 0.210 |
Why?
| | Prevalence | 5 | 2025 | 2815 | 0.200 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 76 | 0.200 |
Why?
| | Likelihood Functions | 1 | 2024 | 143 | 0.200 |
Why?
| | Polysaccharides | 2 | 2017 | 87 | 0.200 |
Why?
| | Risk | 3 | 2016 | 909 | 0.200 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 131 | 0.200 |
Why?
| | C-Reactive Protein | 7 | 2025 | 416 | 0.200 |
Why?
| | Clinical Decision-Making | 2 | 2024 | 358 | 0.200 |
Why?
| | London | 1 | 2023 | 45 | 0.190 |
Why?
| | Africa South of the Sahara | 1 | 2023 | 49 | 0.190 |
Why?
| | Estrogens | 3 | 2017 | 380 | 0.190 |
Why?
| | HLA-DR Antigens | 1 | 2024 | 220 | 0.190 |
Why?
| | Down-Regulation | 1 | 2025 | 627 | 0.190 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.190 |
Why?
| | Autophagy | 1 | 2025 | 285 | 0.190 |
Why?
| | Mouth Mucosa | 3 | 2023 | 88 | 0.190 |
Why?
| | Time Factors | 6 | 2019 | 7155 | 0.190 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 35 | 0.190 |
Why?
| | Trichloroethylene | 1 | 2022 | 8 | 0.190 |
Why?
| | Young Adult | 10 | 2025 | 13990 | 0.180 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 479 | 0.180 |
Why?
| | Periodontal Diseases | 1 | 2023 | 62 | 0.180 |
Why?
| | Patient Education as Topic | 3 | 2018 | 777 | 0.180 |
Why?
| | Insecticide-Treated Bednets | 1 | 2022 | 7 | 0.180 |
Why?
| | Gender Identity | 1 | 2023 | 121 | 0.180 |
Why?
| | Policy | 1 | 2023 | 146 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1128 | 0.180 |
Why?
| | Women's Health | 5 | 2017 | 308 | 0.180 |
Why?
| | Biological Products | 2 | 2022 | 251 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 3 | 2024 | 573 | 0.170 |
Why?
| | Blood Platelets | 1 | 2025 | 399 | 0.170 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 917 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2023 | 216 | 0.170 |
Why?
| | Pulmonary Fibrosis | 1 | 2025 | 395 | 0.170 |
Why?
| | Sex Factors | 5 | 2020 | 2096 | 0.170 |
Why?
| | Organ Specificity | 2 | 2019 | 312 | 0.170 |
Why?
| | Lymphocyte Activation | 1 | 2025 | 1126 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2026 | 2025 | 0.170 |
Why?
| | Housing | 1 | 2022 | 144 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 97 | 0.160 |
Why?
| | Neutrophil Activation | 1 | 2021 | 85 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 101 | 0.160 |
Why?
| | Sarcoidosis | 1 | 2022 | 160 | 0.160 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 9 | 0.160 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.160 |
Why?
| | Hemorrhage | 1 | 2005 | 809 | 0.160 |
Why?
| | Museums | 1 | 2000 | 11 | 0.160 |
Why?
| | T-Lymphocytes | 2 | 2025 | 1982 | 0.160 |
Why?
| | Intestines | 2 | 2021 | 358 | 0.160 |
Why?
| | Sjogren's Syndrome | 1 | 2020 | 37 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 206 | 0.150 |
Why?
| | Severity of Illness Index | 8 | 2022 | 2917 | 0.150 |
Why?
| | Muramidase | 1 | 2020 | 67 | 0.150 |
Why?
| | Public-Private Sector Partnerships | 1 | 2020 | 44 | 0.150 |
Why?
| | Complement System Proteins | 2 | 2022 | 316 | 0.150 |
Why?
| | Pandemics | 2 | 2025 | 1682 | 0.150 |
Why?
| | Art Therapy | 1 | 2000 | 20 | 0.150 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 87 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 194 | 0.150 |
Why?
| | United Kingdom | 1 | 2020 | 336 | 0.150 |
Why?
| | Bacteriophages | 1 | 2021 | 111 | 0.150 |
Why?
| | Attitude | 1 | 2021 | 259 | 0.150 |
Why?
| | Age Factors | 7 | 2020 | 3313 | 0.150 |
Why?
| | Nuclear Family | 1 | 2019 | 52 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2024 | 17009 | 0.150 |
Why?
| | Inflammation Mediators | 2 | 2020 | 508 | 0.140 |
Why?
| | Gene Expression | 2 | 2022 | 1487 | 0.140 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 36 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 48 | 0.140 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 141 | 0.140 |
Why?
| | Dexamethasone | 1 | 2020 | 370 | 0.140 |
Why?
| | Mitochondria | 2 | 2025 | 983 | 0.140 |
Why?
| | Socioeconomic Factors | 4 | 2025 | 1312 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 484 | 0.140 |
Why?
| | Occupational Exposure | 1 | 2022 | 354 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1191 | 0.140 |
Why?
| | Vascular Stiffness | 2 | 2013 | 462 | 0.130 |
Why?
| | Monocytes | 1 | 2020 | 538 | 0.130 |
Why?
| | United States | 9 | 2025 | 15876 | 0.130 |
Why?
| | HLA-DR4 Antigen | 3 | 2007 | 74 | 0.130 |
Why?
| | Cohort Studies | 10 | 2022 | 5935 | 0.130 |
Why?
| | Remission Induction | 2 | 2021 | 306 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2025 | 1091 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 34 | 0.130 |
Why?
| | Metabolome | 1 | 2020 | 384 | 0.130 |
Why?
| | Cellular Senescence | 1 | 2019 | 226 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 394 | 0.120 |
Why?
| | Coronary Disease | 2 | 2017 | 381 | 0.120 |
Why?
| | Glycosylation | 1 | 2017 | 172 | 0.120 |
Why?
| | Seroepidemiologic Studies | 3 | 2014 | 172 | 0.120 |
Why?
| | Decision Making | 1 | 2024 | 974 | 0.120 |
Why?
| | Adiponectin | 1 | 2018 | 243 | 0.120 |
Why?
| | Sex Work | 1 | 2016 | 22 | 0.120 |
Why?
| | Military Personnel | 2 | 2021 | 709 | 0.120 |
Why?
| | Plasma Cells | 1 | 2016 | 75 | 0.120 |
Why?
| | Hydrolases | 2 | 2021 | 55 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2730 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 225 | 0.120 |
Why?
| | Estradiol | 3 | 2017 | 533 | 0.120 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 546 | 0.110 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1983 | 0.110 |
Why?
| | Diagnosis, Differential | 3 | 2013 | 1487 | 0.110 |
Why?
| | Mothers | 1 | 2021 | 774 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2019 | 691 | 0.110 |
Why?
| | Diet | 2 | 2020 | 1271 | 0.110 |
Why?
| | Peptides | 1 | 2021 | 995 | 0.110 |
Why?
| | Neutrophils | 1 | 2021 | 1134 | 0.110 |
Why?
| | Tertiary Prevention | 1 | 2014 | 3 | 0.110 |
Why?
| | Vasodilation | 3 | 2013 | 522 | 0.110 |
Why?
| | Cardiovascular Diseases | 3 | 2017 | 2134 | 0.110 |
Why?
| | Adaptation, Psychological | 1 | 2000 | 706 | 0.110 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1044 | 0.100 |
Why?
| | Alcohol Drinking | 1 | 2020 | 812 | 0.100 |
Why?
| | Blood Pressure | 2 | 2017 | 1759 | 0.100 |
Why?
| | Respiratory Mucosa | 1 | 2016 | 322 | 0.100 |
Why?
| | Neoplasms | 2 | 2017 | 2870 | 0.100 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 163 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 253 | 0.100 |
Why?
| | Bacteroidaceae Infections | 1 | 2012 | 9 | 0.100 |
Why?
| | Family Health | 2 | 2013 | 191 | 0.100 |
Why?
| | Asthma | 1 | 2024 | 1767 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2020 | 940 | 0.090 |
Why?
| | Porphyromonas gingivalis | 1 | 2012 | 23 | 0.090 |
Why?
| | Primary Prevention | 1 | 2014 | 219 | 0.090 |
Why?
| | Vitamin D | 2 | 2022 | 399 | 0.090 |
Why?
| | Immune Tolerance | 1 | 2014 | 379 | 0.090 |
Why?
| | Periodontitis | 1 | 2012 | 54 | 0.090 |
Why?
| | Communicable Disease Control | 2 | 2024 | 86 | 0.090 |
Why?
| | Health | 1 | 2012 | 81 | 0.090 |
Why?
| | Arthrography | 1 | 2011 | 18 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1147 | 0.090 |
Why?
| | Population Surveillance | 1 | 2015 | 483 | 0.090 |
Why?
| | Telomere Shortening | 2 | 2024 | 19 | 0.090 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 113 | 0.090 |
Why?
| | Delayed Diagnosis | 1 | 2012 | 94 | 0.090 |
Why?
| | Disease Susceptibility | 3 | 2021 | 346 | 0.090 |
Why?
| | RNA, Messenger | 3 | 2025 | 2829 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2111 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1322 | 0.080 |
Why?
| | Logistic Models | 5 | 2020 | 2104 | 0.080 |
Why?
| | Labor, Induced | 1 | 2011 | 39 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 97 | 0.080 |
Why?
| | Phenotype | 4 | 2023 | 3157 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2447 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5389 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2011 | 266 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2020 | 3403 | 0.080 |
Why?
| | Time-to-Treatment | 1 | 2012 | 240 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 126 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2012 | 331 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1409 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 427 | 0.080 |
Why?
| | Menopause | 1 | 2012 | 319 | 0.070 |
Why?
| | Colorado | 3 | 2020 | 4562 | 0.070 |
Why?
| | Air Pollution | 1 | 2013 | 326 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 326 | 0.070 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 101 | 0.070 |
Why?
| | Interleukin-6 | 3 | 2021 | 780 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1964 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2021 | 11643 | 0.070 |
Why?
| | Odds Ratio | 3 | 2018 | 1072 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 478 | 0.070 |
Why?
| | Prognosis | 3 | 2026 | 4278 | 0.070 |
Why?
| | Alleles | 3 | 2019 | 878 | 0.070 |
Why?
| | Aspirin | 1 | 2011 | 399 | 0.070 |
Why?
| | Colposcopy | 1 | 2007 | 18 | 0.070 |
Why?
| | Disease Outbreaks | 1 | 2010 | 422 | 0.060 |
Why?
| | Obesity | 1 | 2020 | 3057 | 0.060 |
Why?
| | Brachial Artery | 3 | 2013 | 206 | 0.060 |
Why?
| | Societies, Medical | 2 | 2021 | 886 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 30 | 0.060 |
Why?
| | Stroke | 1 | 2015 | 1254 | 0.060 |
Why?
| | Ultrasonography | 2 | 2025 | 768 | 0.060 |
Why?
| | Zimbabwe | 1 | 2025 | 74 | 0.060 |
Why?
| | Environment | 2 | 2019 | 305 | 0.060 |
Why?
| | Mice | 4 | 2025 | 18329 | 0.060 |
Why?
| | Switzerland | 1 | 2025 | 46 | 0.050 |
Why?
| | Premenopause | 2 | 2017 | 123 | 0.050 |
Why?
| | Capillaries | 1 | 2005 | 124 | 0.050 |
Why?
| | Radiography, Thoracic | 1 | 2005 | 171 | 0.050 |
Why?
| | Healthy Volunteers | 2 | 2017 | 214 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2005 | 227 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 56 | 0.050 |
Why?
| | Receptors, CXCR5 | 1 | 2024 | 27 | 0.050 |
Why?
| | Pregnancy | 2 | 2021 | 7180 | 0.050 |
Why?
| | Quarantine | 1 | 2024 | 31 | 0.050 |
Why?
| | Immunity, Mucosal | 2 | 2014 | 98 | 0.050 |
Why?
| | Interleukin-2 | 2 | 2016 | 437 | 0.050 |
Why?
| | Aminosalicylic Acids | 1 | 2023 | 9 | 0.050 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2023 | 26 | 0.050 |
Why?
| | Prevotella | 1 | 2023 | 26 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 383 | 0.050 |
Why?
| | Vimentin | 1 | 2023 | 54 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2024 | 8243 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 401 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3857 | 0.050 |
Why?
| | Health Policy | 1 | 2025 | 398 | 0.050 |
Why?
| | Biopsy | 1 | 2005 | 1075 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1533 | 0.040 |
Why?
| | Employment | 1 | 2024 | 185 | 0.040 |
Why?
| | Immunoglobulins | 2 | 2015 | 160 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2022 | 327 | 0.040 |
Why?
| | Carotid Arteries | 2 | 2013 | 199 | 0.040 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 35 | 0.040 |
Why?
| | Body Mass Index | 2 | 2020 | 2420 | 0.040 |
Why?
| | Poverty | 1 | 2025 | 523 | 0.040 |
Why?
| | Adolescent | 5 | 2025 | 22281 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 6021 | 0.040 |
Why?
| | Janus Kinase Inhibitors | 1 | 2021 | 28 | 0.040 |
Why?
| | Putrescine | 1 | 2020 | 3 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 331 | 0.040 |
Why?
| | Butyric Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Xenobiotics | 1 | 2021 | 32 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 178 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 176 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 846 | 0.040 |
Why?
| | Spermidine | 1 | 2020 | 17 | 0.040 |
Why?
| | Caprylates | 1 | 2020 | 27 | 0.040 |
Why?
| | Urban Population | 1 | 2024 | 490 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 83 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 287 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.040 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 2 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 76 | 0.040 |
Why?
| | Europe | 1 | 2021 | 412 | 0.040 |
Why?
| | Chemokine CXCL13 | 1 | 2020 | 15 | 0.040 |
Why?
| | Microbiota | 2 | 2021 | 781 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 67 | 0.040 |
Why?
| | Carnitine | 1 | 2020 | 90 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 38 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 67 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1382 | 0.040 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 39 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1172 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 271 | 0.040 |
Why?
| | Child Health | 1 | 2021 | 157 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 687 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 370 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 162 | 0.040 |
Why?
| | Interleukin-1alpha | 1 | 2020 | 57 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 181 | 0.040 |
Why?
| | Ontario | 1 | 2000 | 96 | 0.040 |
Why?
| | Interinstitutional Relations | 1 | 2000 | 53 | 0.040 |
Why?
| | Anxiety | 1 | 2007 | 1104 | 0.040 |
Why?
| | Baltimore | 1 | 2019 | 66 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4556 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 197 | 0.040 |
Why?
| | Tryptophan | 1 | 2020 | 180 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 220 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 668 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 488 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 395 | 0.040 |
Why?
| | Genotype | 2 | 2018 | 1833 | 0.040 |
Why?
| | Rural Population | 1 | 2024 | 648 | 0.040 |
Why?
| | Interferons | 1 | 2020 | 188 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2018 | 20 | 0.030 |
Why?
| | Dysbiosis | 1 | 2020 | 187 | 0.030 |
Why?
| | Forecasting | 1 | 2020 | 388 | 0.030 |
Why?
| | Nurses | 1 | 2020 | 178 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 621 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3119 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 481 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 672 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 318 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 2143 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 478 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 496 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.030 |
Why?
| | Child | 4 | 2025 | 22537 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1313 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 21 | 0.030 |
Why?
| | Raloxifene Hydrochloride | 1 | 2017 | 15 | 0.030 |
Why?
| | Leuprolide | 1 | 2017 | 21 | 0.030 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2017 | 36 | 0.030 |
Why?
| | Amino Acids | 1 | 2021 | 521 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 4 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 16 | 0.030 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2017 | 52 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2021 | 454 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 1015 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 69 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 75 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 889 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 99 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 736 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 677 | 0.030 |
Why?
| | Androgens | 1 | 2017 | 186 | 0.030 |
Why?
| | Health Education | 1 | 2018 | 357 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2000 | 704 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2017 | 212 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1519 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2016 | 137 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 316 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2015 | 92 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1044 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1255 | 0.030 |
Why?
| | Child, Preschool | 2 | 2025 | 11774 | 0.030 |
Why?
| | Etanercept | 1 | 2013 | 60 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2014 | 109 | 0.020 |
Why?
| | Motivation | 1 | 2018 | 605 | 0.020 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 12 | 0.020 |
Why?
| | Geographic Information Systems | 1 | 2013 | 46 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 549 | 0.020 |
Why?
| | Testosterone | 1 | 2017 | 419 | 0.020 |
Why?
| | Interleukin-9 | 1 | 2012 | 12 | 0.020 |
Why?
| | Oral Health | 1 | 2014 | 139 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 706 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1646 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 307 | 0.020 |
Why?
| | Communication | 1 | 2018 | 961 | 0.020 |
Why?
| | Life Style | 1 | 2014 | 475 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 575 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2014 | 255 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 161 | 0.020 |
Why?
| | Connective Tissue Diseases | 1 | 2012 | 84 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1054 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4085 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 338 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 377 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 757 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 347 | 0.020 |
Why?
| | Internet | 1 | 2014 | 698 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 704 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2193 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 606 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 784 | 0.020 |
Why?
| | Self Report | 1 | 2013 | 863 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2603 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 121 | 0.020 |
Why?
| | Hypertension | 1 | 2015 | 1254 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1092 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1834 | 0.020 |
Why?
| | Veterans | 1 | 2018 | 1600 | 0.010 |
Why?
| | Tobacco Smoke Pollution | 1 | 2007 | 233 | 0.010 |
Why?
| | Siblings | 1 | 2005 | 195 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 267 | 0.010 |
Why?
| | Pain | 1 | 2007 | 777 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1705 | 0.010 |
Why?
| | Arthritis, Infectious | 1 | 1994 | 72 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2006 | 3842 | 0.000 |
Why?
|
|
Deane's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|